Display options
Cite
Saint CA, Castelli MR, Crannage AJ, et al. Comparison of hospital length of stay in patients treated with non-vitamin K oral anticoagulants or parenteral agents plus warfarin for venous thromboembolism. SAGE Open Med. 2017;5:2050312117719628doi: 10.1177/2050312117719628.
Saint, C. A., Castelli, M. R., Crannage, A. J., Stacy, Z. A., & Hennessey, E. K. (2017). Comparison of hospital length of stay in patients treated with non-vitamin K oral anticoagulants or parenteral agents plus warfarin for venous thromboembolism. SAGE open medicine, 52050312117719628. https://doi.org/10.1177/2050312117719628
Saint, Catherine A, et al. "Comparison of hospital length of stay in patients treated with non-vitamin K oral anticoagulants or parenteral agents plus warfarin for venous thromboembolism." SAGE open medicine vol. 5 (2017): 2050312117719628. doi: https://doi.org/10.1177/2050312117719628
Saint CA, Castelli MR, Crannage AJ, Stacy ZA, Hennessey EK. Comparison of hospital length of stay in patients treated with non-vitamin K oral anticoagulants or parenteral agents plus warfarin for venous thromboembolism. SAGE Open Med. 2017 Jul 18;5:2050312117719628. doi: 10.1177/2050312117719628. eCollection 2017. PMID: 28781876; PMCID: PMC5521330.
Copy Download .nbib Format: NLM
Share it on

SAGE Open Med. 2017 Jul 18;5:2050312117719628. doi: 10.1177/2050312117719628. eCollection 2017.

Comparison of hospital length of stay in patients treated with non-vitamin K oral anticoagulants or parenteral agents plus warfarin for venous thromboembolism.

SAGE open medicine

Catherine A Saint, Michelle R Castelli, Andrew J Crannage, Zachary A Stacy, Erin K Hennessey

Affiliations

  1. Mercy Hospital St. Louis, St. Louis, MO, USA.
  2. UC San Diego Health, San Diego, CA, USA.
  3. St. Louis College of Pharmacy, St. Louis, MO, USA.

PMID: 28781876 PMCID: PMC5521330 DOI: 10.1177/2050312117719628

Abstract

OBJECTIVES: Existing research comparing hospital length of stay for patients treated with non-vitamin K oral anticoagulants or parenteral bridging to warfarin has been conducted primarily with the agent rivaroxaban. The objective of this study was to compare hospital length of stay between patients initiated on the non-vitamin K oral anticoagulants, apixaban or rivaroxaban, and patients initiated on parenteral anticoagulation agents plus warfarin for the treatment of venous thromboembolism.

METHODS: A retrospective cohort study was conducted at an 859-bed, not-for-profit, teaching hospital. Adult patients admitted for a primary diagnosis of venous thromboembolism between 1 November 2012 and 31 August 2015 and treated with apixaban or rivaroxaban or a parenteral anticoagulant plus warfarin were included in the study. Eligible patients were identified using

RESULTS: A total of 152 patients were included in this study. Patient characteristics, including renal function, were similar between study arms. Venous thromboembolism treatment with apixaban or rivaroxaban compared to a parenteral anticoagulant plus warfarin was associated with a reduced hospital length of stay (2.63 vs 5.33 days; p < 0.05) and decreased total hospital cost adjusted to 2015 dollars (US$21,694 vs US$38,851; p = 0.013).

CONCLUSION: These results suggest that treatment with a non-vitamin K anticoagulant may significantly reduce hospital length of stay and total hospital cost compared to a parenteral anticoagulant plus warfarin for patients admitted for venous thromboembolism.

Keywords: Adult medicine; anticoagulants; anticoagulation; cardiology; clinical practice; cost benefit; disease management; hematology; warfarin

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Z.A. Stacy is a

References

  1. Chest. 2012 Feb;141(2 Suppl):7S-47S - PubMed
  2. Intern Emerg Med. 2017 Apr;12 (3):311-318 - PubMed
  3. J Med Econ. 2016 Aug;19(8):769-76 - PubMed
  4. Kardiol Pol. 2016;74(7):650-6 - PubMed
  5. Clin Ther. 2015 Mar 1;37(3):554-62 - PubMed
  6. Curr Med Res Opin. 2014 May;30(5):829-37 - PubMed
  7. Pharmacotherapy. 2016 Oct;36(10 ):1109-1115 - PubMed
  8. Chest. 2016 Feb;149(2):315-52 - PubMed
  9. Hosp Pract (1995). 2015;43(2):85-93 - PubMed
  10. Curr Med Res Opin. 2015 Jun;31(6):1057-61 - PubMed
  11. J Am Heart Assoc. 2016 Oct 6;5(10 ):null - PubMed
  12. Clin Appl Thromb Hemost. 2016 Jan 1;:1076029616661415 - PubMed
  13. Curr Med Res Opin. 2014 Apr;30(4):645-53 - PubMed
  14. J Med Econ. 2014 Oct;17(10):691-5 - PubMed
  15. J Am Heart Assoc. 2015 Dec 01;4(12):null - PubMed
  16. Lung. 2016 Aug;194(4):605-11 - PubMed
  17. Clin Ther. 2016 Nov;38(11):2496-2503 - PubMed
  18. Thrombosis. 2015;2015:414523 - PubMed
  19. Hosp Pract (1995). 2015;43(3):172-9 - PubMed

Publication Types